Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
35 36 Next >
Could Latecomer Moderna Match Big Pharma Rivals in RSV?
RSV is a key part of Moderna's respiratory vaccine business. 
Via The Motley Fool
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
The U.S. 
Via Benzinga
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?
GSK plc (NYSE: GSK) presented preliminary results from the phase 3 trial of imm 
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have  
Via Benzinga
GSK Trims Stake On Consumer Business Spin Off, Raises £804M
GSK Plc (NYSE: GSK) sold 240 mi 
Via Benzinga
GSK Stock: A Value Trap or a Hidden Gem?
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy. 
Via InvestorPlace
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
Via Benzinga
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies. 
Via Investor's Business Daily
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
RSV could be the next big battleground for big pharma -- but it could soon become crowded. 
Via The Motley Fool
Dividend Income Update April 2023
With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated. 
Via Talk Markets
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug 
Via MarketBeat
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
The World Health Organization ended the global emergency 
Via Benzinga
GSK: Add This Cheap Chip Play To Your Portfolio
GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%. 
Via Talk Markets
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
From HKTDC
Via ACN Newswire
A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market
The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in... 
Via Benzinga
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
From GSK plc
Via Business Wire
GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line
GSK won FDA approval for the first-ever RSV vaccine for older adults. 
Via Investor's Business Daily
KVUE Stock: Should You Buy Into the Kenvue IPO?
KVUE stock will be a dividend stock with an initial yield of 3.5%, with slow growth and lower margins than JNJ's drug business. 
Via InvestorPlace
Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says
Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN).  
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
The company reported lighter-than-expected declines due to Keytruda and Gardasil. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
Both GSK and Roche experienced declining Covid-related sales in the first quarter. 
Via Investor's Business Daily
Was This Acquisition a Savvy Play by This Big Pharma Stock?
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health. 
Via The Motley Fool
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.